市場調査レポート
商品コード
1299620

非小細胞肺がん治療薬の世界市場 2023-2027

Global Non-small Cell Lung Cancer Drugs Market 2023-2027

出版日: | 発行: TechNavio | ページ情報: 英文 167 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
非小細胞肺がん治療薬の世界市場 2023-2027
出版日: 2023年05月25日
発行: TechNavio
ページ情報: 英文 167 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

非小細胞肺がん治療薬市場は2022-2027年に159億3,689万米ドル、予測期間中のCAGRは9.25%で成長すると予測されています。

この調査レポートは、非小細胞肺がん治療薬市場の全体分析、市場規模、予測、動向、市場促進要因・促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、非小細胞肺がんの有病率と罹患率の増加、強力な医薬品パイプラインと最近の医薬品承認、患者支援プログラムの利用可能性によって牽引されています。

本調査では、併用療法のイントロダクションと承認が、今後数年間の非小細胞肺がん治療薬市場成長を牽引する主要因の1つであるとしています。また、非小細胞肺がん治療薬を開発するための戦略的提携の増加や、費用対効果の高い治療法を開発するための予測バイオマーカーの使用は、市場の大きな需要につながるでしょう。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場エコシステム

第3章 市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模 2022
  • 市場の見通し 2022-2027

第4章 市場規模実績

  • 非小細胞肺がん治療薬の世界市場 2017-2021
  • タイプセグメント分析 2017-2021
  • 製品セグメント分析 2017-2021
  • 地域別セグメント分析 2017-2021
  • 国別セグメント分析 2017-2021

第5章 ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

第6章 市場セグメンテーション:タイプ別

  • 市場セグメント
  • 比較:タイプ別
  • 腺がん:市場規模と予測 2022-2027
  • 扁平上皮がん:市場規模と予測 2022-2027
  • 大細胞がん:市場規模と予測 2022-2027
  • 市場機会:タイプ別

第7章 市場セグメンテーション:製品別

  • 市場セグメント
  • 比較:製品別
  • 生物製剤:市場規模と予測 2022-2027
  • 低分子標的療法:市場規模と予測 2022-2027
  • 化学療法:市場規模と予測 2022-2027
  • 市場機会:製品別

第8章 顧客情勢

  • 顧客情勢の概要

第9章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米:市場規模と予測 2022-2027
  • 欧州:市場規模と予測 2022-2027
  • アジア:市場規模と予測 2022-2027
  • 世界のその他の地域:市場規模と予測 2022-2027
  • 米国:市場規模と予測 2022-2027
  • ドイツ:市場規模と予測 2022-2027
  • 中国:市場規模と予測 2022-2027
  • カナダ:市場規模と予測 2022-2027
  • 英国:市場規模と予測 2022-2027
  • 地域情勢別市場機会

第10章 促進要因、課題、および動向

  • 市場促進要因
  • 市場の課題
  • 促進要因と課題の影響
  • 市場動向

第11章 ベンダー情勢

  • 概要
  • ベンダー情勢
  • 混乱の状況
  • 業界のリスク

第12章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Innovent Biologics Inc.
  • Merck KGaA
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.

第13章 付録

図表

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Type
  • Exhibits6: Executive Summary - Chart on Market Segmentation by Product
  • Exhibits7: Executive Summary - Chart on Incremental Growth
  • Exhibits8: Executive Summary - Data Table on Incremental Growth
  • Exhibits9: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits10: Parent market
  • Exhibits11: Market Characteristics
  • Exhibits12: Offerings of vendors included in the market definition
  • Exhibits13: Market segments
  • Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits18: Historic Market Size - Data Table on global non-small cell lung cancer drugs market 2017 - 2021 ($ million)
  • Exhibits19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
  • Exhibits20: Historic Market Size - Product Segment 2017 - 2021 ($ million)
  • Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
  • Exhibits23: Five forces analysis - Comparison between 2022 and 2027
  • Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • Exhibits29: Chart on Market condition - Five forces 2022 and 2027
  • Exhibits30: Chart on Type - Market share 2022-2027 (%)
  • Exhibits31: Data Table on Type - Market share 2022-2027 (%)
  • Exhibits32: Chart on Comparison by Type
  • Exhibits33: Data Table on Comparison by Type
  • Exhibits34: Chart on Adenocarcinoma - Market size and forecast 2022-2027 ($ million)
  • Exhibits35: Data Table on Adenocarcinoma - Market size and forecast 2022-2027 ($ million)
  • Exhibits36: Chart on Adenocarcinoma - Year-over-year growth 2022-2027 (%)
  • Exhibits37: Data Table on Adenocarcinoma - Year-over-year growth 2022-2027 (%)
  • Exhibits38: Chart on Squamous cell carcinoma - Market size and forecast 2022-2027 ($ million)
  • Exhibits39: Data Table on Squamous cell carcinoma - Market size and forecast 2022-2027 ($ million)
  • Exhibits40: Chart on Squamous cell carcinoma - Year-over-year growth 2022-2027 (%)
  • Exhibits41: Data Table on Squamous cell carcinoma - Year-over-year growth 2022-2027 (%)
  • Exhibits42: Chart on Large cell carcinoma - Market size and forecast 2022-2027 ($ million)
  • Exhibits43: Data Table on Large cell carcinoma - Market size and forecast 2022-2027 ($ million)
  • Exhibits44: Chart on Large cell carcinoma - Year-over-year growth 2022-2027 (%)
  • Exhibits45: Data Table on Large cell carcinoma - Year-over-year growth 2022-2027 (%)
  • Exhibits46: Market opportunity by Type ($ million)
  • Exhibits47: Data Table on Market opportunity by Type ($ million)
  • Exhibits48: Chart on Product - Market share 2022-2027 (%)
  • Exhibits49: Data Table on Product - Market share 2022-2027 (%)
  • Exhibits50: Chart on Comparison by Product
  • Exhibits51: Data Table on Comparison by Product
  • Exhibits52: Chart on Biologics - Market size and forecast 2022-2027 ($ million)
  • Exhibits53: Data Table on Biologics - Market size and forecast 2022-2027 ($ million)
  • Exhibits54: Chart on Biologics - Year-over-year growth 2022-2027 (%)
  • Exhibits55: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
  • Exhibits56: Chart on Small molecule targeted therapy - Market size and forecast 2022-2027 ($ million)
  • Exhibits57: Data Table on Small molecule targeted therapy - Market size and forecast 2022-2027 ($ million)
  • Exhibits58: Chart on Small molecule targeted therapy - Year-over-year growth 2022-2027 (%)
  • Exhibits59: Data Table on Small molecule targeted therapy - Year-over-year growth 2022-2027 (%)
  • Exhibits60: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ million)
  • Exhibits61: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ million)
  • Exhibits62: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%)
  • Exhibits63: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%)
  • Exhibits64: Market opportunity by Product ($ million)
  • Exhibits65: Data Table on Market opportunity by Product ($ million)
  • Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits67: Chart on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibits68: Data Table on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibits69: Chart on Geographic comparison
  • Exhibits70: Data Table on Geographic comparison
  • Exhibits71: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits73: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits74: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits77: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits81: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits87: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits88: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits89: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibits90: Data Table on US - Year-over-year growth 2022-2027 (%)
  • Exhibits91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibits92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibits93: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibits94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibits95: Chart on China - Market size and forecast 2022-2027 ($ million)
  • Exhibits96: Data Table on China - Market size and forecast 2022-2027 ($ million)
  • Exhibits97: Chart on China - Year-over-year growth 2022-2027 (%)
  • Exhibits98: Data Table on China - Year-over-year growth 2022-2027 (%)
  • Exhibits99: Chart on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibits100: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibits101: Chart on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibits102: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibits103: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibits104: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibits105: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibits106: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • Exhibits107: Market opportunity By Geographical Landscape ($ million)
  • Exhibits108: Data Tables on Market opportunity By Geographical Landscape ($ million)
  • Exhibits109: Impact of drivers and challenges in 2022 and 2027
  • Exhibits110: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits111: Overview on factors of disruption
  • Exhibits112: Impact of key risks on business
  • Exhibits113: Vendors covered
  • Exhibits114: Matrix on vendor position and classification
  • Exhibits115: AbbVie Inc. - Overview
  • Exhibits116: AbbVie Inc. - Product / Service
  • Exhibits117: AbbVie Inc. - Key news
  • Exhibits118: AbbVie Inc. - Key offerings
  • Exhibits119: Amgen Inc. - Overview
  • Exhibits120: Amgen Inc. - Product / Service
  • Exhibits121: Amgen Inc. - Key offerings
  • Exhibits122: Astellas Pharma Inc. - Overview
  • Exhibits123: Astellas Pharma Inc. - Product / Service
  • Exhibits124: Astellas Pharma Inc. - Key news
  • Exhibits125: Astellas Pharma Inc. - Key offerings
  • Exhibits126: AstraZeneca PLC - Overview
  • Exhibits127: AstraZeneca PLC - Product / Service
  • Exhibits128: AstraZeneca PLC - Key news
  • Exhibits129: AstraZeneca PLC - Key offerings
  • Exhibits130: Bayer AG - Overview
  • Exhibits131: Bayer AG - Business segments
  • Exhibits132: Bayer AG - Key news
  • Exhibits133: Bayer AG - Key offerings
  • Exhibits134: Bayer AG - Segment focus
  • Exhibits135: BeiGene Ltd. - Overview
  • Exhibits136: BeiGene Ltd. - Business segments
  • Exhibits137: BeiGene Ltd. - Key offerings
  • Exhibits138: BeiGene Ltd. - Segment focus
  • Exhibits139: Boehringer Ingelheim International GmbH - Overview
  • Exhibits140: Boehringer Ingelheim International GmbH - Business segments
  • Exhibits141: Boehringer Ingelheim International GmbH - Key news
  • Exhibits142: Boehringer Ingelheim International GmbH - Key offerings
  • Exhibits143: Boehringer Ingelheim International GmbH - Segment focus
  • Exhibits144: Bristol Myers Squibb Co. - Overview
  • Exhibits145: Bristol Myers Squibb Co. - Product / Service
  • Exhibits146: Bristol Myers Squibb Co. - Key news
  • Exhibits147: Bristol Myers Squibb Co. - Key offerings
  • Exhibits148: Eli Lilly and Co. - Overview
  • Exhibits149: Eli Lilly and Co. - Product / Service
  • Exhibits150: Eli Lilly and Co. - Key news
  • Exhibits151: Eli Lilly and Co. - Key offerings
  • Exhibits152: F. Hoffmann La Roche Ltd. - Overview
  • Exhibits153: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibits154: F. Hoffmann La Roche Ltd. - Key news
  • Exhibits155: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibits156: F. Hoffmann La Roche Ltd. - Segment focus
  • Exhibits157: Innovent Biologics Inc. - Overview
  • Exhibits158: Innovent Biologics Inc. - Product / Service
  • Exhibits159: Innovent Biologics Inc. - Key offerings
  • Exhibits160: Merck KGaA - Overview
  • Exhibits161: Merck KGaA - Business segments
  • Exhibits162: Merck KGaA - Key news
  • Exhibits163: Merck KGaA - Key offerings
  • Exhibits164: Merck KGaA - Segment focus
  • Exhibits165: Ono Pharmaceutical Co. Ltd. - Overview
  • Exhibits166: Ono Pharmaceutical Co. Ltd. - Product / Service
  • Exhibits167: Ono Pharmaceutical Co. Ltd. - Key offerings
  • Exhibits168: Pfizer Inc. - Overview
  • Exhibits169: Pfizer Inc. - Product / Service
  • Exhibits170: Pfizer Inc. - Key news
  • Exhibits171: Pfizer Inc. - Key offerings
  • Exhibits172: Takeda Pharmaceutical Co. Ltd. - Overview
  • Exhibits173: Takeda Pharmaceutical Co. Ltd. - Product / Service
  • Exhibits174: Takeda Pharmaceutical Co. Ltd. - Key news
  • Exhibits175: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • Exhibits176: Inclusions checklist
  • Exhibits177: Exclusions checklist
  • Exhibits178: Currency conversion rates for US$
  • Exhibits179: Research methodology
  • Exhibits180: Validation techniques employed for market sizing
  • Exhibits181: Information sources
  • Exhibits182: List of abbreviations
目次
Product Code: IRTNTR72354

The non-small cell lung cancer drugs market is forecasted to grow by USD 15936.89 mn during 2022-2027, accelerating at a CAGR of 9.25% during the forecast period. The report on the non-small cell lung cancer drugs market provides a holistic analysis, market size, and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence and incidence of non-small cell lung cancer, the strong drug pipeline and recent drug approvals, and the availability of patient assistance programs.

Technavio's non-small cell lung cancer drugs market is segmented as below:

By Type

  • Adenocarcinoma
  • Squamous cell carcinoma
  • Large cell carcinoma

By Product

  • Biologics
  • Small molecule targeted therapy
  • Chemotherapy

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the introduction and approval of combination therapies as one of the prime reasons driving the non-small cell lung cancer drugs market growth during the next few years. Also, an increase in strategic alliances to develop non-small cell lung cancer drugs and the use of predictive biomarkers for the development of cost-effective therapies will lead to sizable demand in the market.

The report on the non-small cell lung cancer drugs market covers the following areas:

  • Non-small cell lung cancer drugs market sizing
  • Non-small cell lung cancer drugs market forecast
  • Non-small cell lung cancer drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading non-small cell lung cancer drugs market vendors that include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck KGaA, Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., PharmaMar SA, Regeneron Pharmaceuticals Inc., Sanofi, and Takeda Pharmaceutical Co. Ltd.. Also, the non-small cell lung cancer drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Product
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027
  • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global non-small cell lung cancer drugs market 2017 - 2021
  • Exhibit 18: Historic Market Size - Data Table on global non-small cell lung cancer drugs market 2017 - 2021 ($ million)
  • 4.2 Type Segment Analysis 2017 - 2021
  • Exhibit 19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
  • 4.3 Product Segment Analysis 2017 - 2021
  • Exhibit 20: Historic Market Size - Product Segment 2017 - 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 - 2021
  • Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 - 2021
  • Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Type

  • 6.1 Market segments
  • Exhibit 30: Chart on Type - Market share 2022-2027 (%)
  • Exhibit 31: Data Table on Type - Market share 2022-2027 (%)
  • 6.2 Comparison by Type
  • Exhibit 32: Chart on Comparison by Type
  • Exhibit 33: Data Table on Comparison by Type
  • 6.3 Adenocarcinoma - Market size and forecast 2022-2027
  • Exhibit 34: Chart on Adenocarcinoma - Market size and forecast 2022-2027 ($ million)
  • Exhibit 35: Data Table on Adenocarcinoma - Market size and forecast 2022-2027 ($ million)
  • Exhibit 36: Chart on Adenocarcinoma - Year-over-year growth 2022-2027 (%)
  • Exhibit 37: Data Table on Adenocarcinoma - Year-over-year growth 2022-2027 (%)
  • 6.4 Squamous cell carcinoma - Market size and forecast 2022-2027
  • Exhibit 38: Chart on Squamous cell carcinoma - Market size and forecast 2022-2027 ($ million)
  • Exhibit 39: Data Table on Squamous cell carcinoma - Market size and forecast 2022-2027 ($ million)
  • Exhibit 40: Chart on Squamous cell carcinoma - Year-over-year growth 2022-2027 (%)
  • Exhibit 41: Data Table on Squamous cell carcinoma - Year-over-year growth 2022-2027 (%)
  • 6.5 Large cell carcinoma - Market size and forecast 2022-2027
  • Exhibit 42: Chart on Large cell carcinoma - Market size and forecast 2022-2027 ($ million)
  • Exhibit 43: Data Table on Large cell carcinoma - Market size and forecast 2022-2027 ($ million)
  • Exhibit 44: Chart on Large cell carcinoma - Year-over-year growth 2022-2027 (%)
  • Exhibit 45: Data Table on Large cell carcinoma - Year-over-year growth 2022-2027 (%)
  • 6.6 Market opportunity by Type
  • Exhibit 46: Market opportunity by Type ($ million)
  • Exhibit 47: Data Table on Market opportunity by Type ($ million)

7 Market Segmentation by Product

  • 7.1 Market segments
  • Exhibit 48: Chart on Product - Market share 2022-2027 (%)
  • Exhibit 49: Data Table on Product - Market share 2022-2027 (%)
  • 7.2 Comparison by Product
  • Exhibit 50: Chart on Comparison by Product
  • Exhibit 51: Data Table on Comparison by Product
  • 7.3 Biologics - Market size and forecast 2022-2027
  • Exhibit 52: Chart on Biologics - Market size and forecast 2022-2027 ($ million)
  • Exhibit 53: Data Table on Biologics - Market size and forecast 2022-2027 ($ million)
  • Exhibit 54: Chart on Biologics - Year-over-year growth 2022-2027 (%)
  • Exhibit 55: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
  • 7.4 Small molecule targeted therapy - Market size and forecast 2022-2027
  • Exhibit 56: Chart on Small molecule targeted therapy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 57: Data Table on Small molecule targeted therapy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 58: Chart on Small molecule targeted therapy - Year-over-year growth 2022-2027 (%)
  • Exhibit 59: Data Table on Small molecule targeted therapy - Year-over-year growth 2022-2027 (%)
  • 7.5 Chemotherapy - Market size and forecast 2022-2027
  • Exhibit 60: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 61: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 62: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%)
  • Exhibit 63: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%)
  • 7.6 Market opportunity by Product
  • Exhibit 64: Market opportunity by Product ($ million)
  • Exhibit 65: Data Table on Market opportunity by Product ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 67: Chart on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibit 68: Data Table on Market share By Geographical Landscape 2022-2027 (%)
  • 9.2 Geographic comparison
  • Exhibit 69: Chart on Geographic comparison
  • Exhibit 70: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2022-2027
  • Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • 9.4 Europe - Market size and forecast 2022-2027
  • Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • 9.5 Asia - Market size and forecast 2022-2027
  • Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
  • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • 9.7 US - Market size and forecast 2022-2027
  • Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
  • 9.8 Germany - Market size and forecast 2022-2027
  • Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • 9.9 China - Market size and forecast 2022-2027
  • Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
  • Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)
  • 9.10 Canada - Market size and forecast 2022-2027
  • Exhibit 99: Chart on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 100: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 101: Chart on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibit 102: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • 9.11 UK - Market size and forecast 2022-2027
  • Exhibit 103: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 104: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 105: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibit 106: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity By Geographical Landscape
  • Exhibit 107: Market opportunity By Geographical Landscape ($ million)
  • Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 109: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 111: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 112: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 113: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 114: Matrix on vendor position and classification
  • 12.3 AbbVie Inc.
  • Exhibit 115: AbbVie Inc. - Overview
  • Exhibit 116: AbbVie Inc. - Product / Service
  • Exhibit 117: AbbVie Inc. - Key news
  • Exhibit 118: AbbVie Inc. - Key offerings
  • 12.4 Amgen Inc.
  • Exhibit 119: Amgen Inc. - Overview
  • Exhibit 120: Amgen Inc. - Product / Service
  • Exhibit 121: Amgen Inc. - Key offerings
  • 12.5 Astellas Pharma Inc.
  • Exhibit 122: Astellas Pharma Inc. - Overview
  • Exhibit 123: Astellas Pharma Inc. - Product / Service
  • Exhibit 124: Astellas Pharma Inc. - Key news
  • Exhibit 125: Astellas Pharma Inc. - Key offerings
  • 12.6 AstraZeneca PLC
  • Exhibit 126: AstraZeneca PLC - Overview
  • Exhibit 127: AstraZeneca PLC - Product / Service
  • Exhibit 128: AstraZeneca PLC - Key news
  • Exhibit 129: AstraZeneca PLC - Key offerings
  • 12.7 Bayer AG
  • Exhibit 130: Bayer AG - Overview
  • Exhibit 131: Bayer AG - Business segments
  • Exhibit 132: Bayer AG - Key news
  • Exhibit 133: Bayer AG - Key offerings
  • Exhibit 134: Bayer AG - Segment focus
  • 12.8 BeiGene Ltd.
  • Exhibit 135: BeiGene Ltd. - Overview
  • Exhibit 136: BeiGene Ltd. - Business segments
  • Exhibit 137: BeiGene Ltd. - Key offerings
  • Exhibit 138: BeiGene Ltd. - Segment focus
  • 12.9 Boehringer Ingelheim International GmbH
  • Exhibit 139: Boehringer Ingelheim International GmbH - Overview
  • Exhibit 140: Boehringer Ingelheim International GmbH - Business segments
  • Exhibit 141: Boehringer Ingelheim International GmbH - Key news
  • Exhibit 142: Boehringer Ingelheim International GmbH - Key offerings
  • Exhibit 143: Boehringer Ingelheim International GmbH - Segment focus
  • 12.10 Bristol Myers Squibb Co.
  • Exhibit 144: Bristol Myers Squibb Co. - Overview
  • Exhibit 145: Bristol Myers Squibb Co. - Product / Service
  • Exhibit 146: Bristol Myers Squibb Co. - Key news
  • Exhibit 147: Bristol Myers Squibb Co. - Key offerings
  • 12.11 Eli Lilly and Co.
  • Exhibit 148: Eli Lilly and Co. - Overview
  • Exhibit 149: Eli Lilly and Co. - Product / Service
  • Exhibit 150: Eli Lilly and Co. - Key news
  • Exhibit 151: Eli Lilly and Co. - Key offerings
  • 12.12 F. Hoffmann La Roche Ltd.
  • Exhibit 152: F. Hoffmann La Roche Ltd. - Overview
  • Exhibit 153: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibit 154: F. Hoffmann La Roche Ltd. - Key news
  • Exhibit 155: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibit 156: F. Hoffmann La Roche Ltd. - Segment focus
  • 12.13 Innovent Biologics Inc.
  • Exhibit 157: Innovent Biologics Inc. - Overview
  • Exhibit 158: Innovent Biologics Inc. - Product / Service
  • Exhibit 159: Innovent Biologics Inc. - Key offerings
  • 12.14 Merck KGaA
  • Exhibit 160: Merck KGaA - Overview
  • Exhibit 161: Merck KGaA - Business segments
  • Exhibit 162: Merck KGaA - Key news
  • Exhibit 163: Merck KGaA - Key offerings
  • Exhibit 164: Merck KGaA - Segment focus
  • 12.15 Ono Pharmaceutical Co. Ltd.
  • Exhibit 165: Ono Pharmaceutical Co. Ltd. - Overview
  • Exhibit 166: Ono Pharmaceutical Co. Ltd. - Product / Service
  • Exhibit 167: Ono Pharmaceutical Co. Ltd. - Key offerings
  • 12.16 Pfizer Inc.
  • Exhibit 168: Pfizer Inc. - Overview
  • Exhibit 169: Pfizer Inc. - Product / Service
  • Exhibit 170: Pfizer Inc. - Key news
  • Exhibit 171: Pfizer Inc. - Key offerings
  • 12.17 Takeda Pharmaceutical Co. Ltd.
  • Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Overview
  • Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Product / Service
  • Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Key news
  • Exhibit 175: Takeda Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 176: Inclusions checklist
  • Exhibit 177: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 178: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 179: Research methodology
  • Exhibit 180: Validation techniques employed for market sizing
  • Exhibit 181: Information sources
  • 13.5 List of abbreviations
  • Exhibit 182: List of abbreviations